Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
This is used to treat central diabetes insipidus and bedwetting
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
The state-of-the-art facility is equipped with best-in-class equipment and control systems
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
New solvent-free micronization technology expanded at the Darmstadt site in Germany
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Subscribe To Our Newsletter & Stay Updated
